A Phase 3 interventional study of Filgrastim in Repeated Embryo Implantation Failure, sponsored by Clinique Ovo. Terminated at 1 site in Canada. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2022-04-27.
Sponsored by Clinique Ovo · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Infertility by Clinique Ovo — none open to participants now, none under way, none of them phase 3. Infertility · Clinique Ovo.
Among the 20 studies in Infertility by Clinique Ovo, this one is one of 2 that started in 2013, is one of 2 in phase 3, and was the 10th registered.
2,089 studies on the registry are indexed under Infertility; 356 are open to participants now.
Browse Infertility studies →None of the 20 studies in Infertility by Clinique Ovo is open now. The open studies under Infertility, anywhere →
Of the 234 Infertility studies recruiting now, 43 (18%) set no upper age limit and 185 (79%) stop at 75 or younger; 27 take children under 18; 76 take healthy volunteers.
This study: 18 Years to 37 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 2 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 15 is below the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 207 across the 9 interventional studies, 118 across the 11 observational. Of the 18 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Clinique Ovo is the lead sponsor of 36 studies on the registry; 1 is open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Infertility by Clinique Ovo, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to see the impact of intrauterine injection of recombinant GCSF on pregnancy and implantation rate during IVF-ICSI (intracytoplasmic sperm injection) protocols as well as in frozen embryo transfer. In addition, following the injection, the level of G-CSF in the bloodstream will be verified.
Recently, scientists have been interested in G-CSF (Granulocyte - Colony Stimulating Factor) and the latter has seen its use grow in reproductive pathology.
G -CSF, a true center pivot, would act concurrently on oocyte quality and endometrial receptivity, improving:
The injection of G-CSF molecule has been used in different circumstances. One of its uses, among others, is to help rebuild the immune system in patients undergoing chemotherapy. Some studies have been conducted in patients having embryo implantation problems; they have demonstrated improved rates of pregnancy and childbirth after treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Injection Filgrastim 300 ug intravaginally during an IVF cycle or during an embryo transfer
Drug: Filgrastim
Injection of 1 ml of Sodium Chloride intravaginally during an IVF cycle or during an embryo transfer cycle.
Drug: Filgrastim
The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
Also known as: Neupogen
Dosage of G-CSF
Measure dosage of G-CSF in the bloodstream on the day of oocyte retrieval and measure the implantation rate as well as pregnancy rate following the G-CSF injection
Time frame: up to 3 years
Pregnancy and Implantation
Measure the pregnancy and embryo implantation rate post G-CSF injection
Time frame: up to 3 years
Ran from Mar 2013 to primary completion in Dec 2017, 57 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim